Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Net Margin (2017 - 2025)

Autolus Therapeutics' Net Margin history spans 6 years, with the latest figure at 371.9% for Q4 2025.

  • For Q4 2025, Net Margin rose 9482120.0% year-over-year to 371.9%; the TTM value through Dec 2025 reached 381.4%, up 179712.0%, while the annual FY2025 figure was 381.4%, 179906.0% up from the prior year.
  • Net Margin reached 371.9% in Q4 2025 per AUTL's latest filing, roughly flat from 373.3% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 229.02% in Q2 2025 to a low of 95193.1% in Q4 2024.
  • Average Net Margin over 4 years is 14907.87%, with a median of 781.13% recorded in 2025.
  • The largest YoY upside for Net Margin was 9482120bps in 2025 against a maximum downside of -25945bps in 2025.
  • A 4-year view of Net Margin shows it stood at 22326.51% in 2022, then skyrocketed by 49bps to 11292.86% in 2023, then tumbled by -743bps to 95193.1% in 2024, then soared by 100bps to 371.9% in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Net Margin are 371.9% (Q4 2025), 373.3% (Q3 2025), and 229.02% (Q2 2025).